You just read:

US Nephrologists Beginning to Trial AstraZeneca's LOKELMA (zirconium sodium cyclosilicate) but Unclear on Differentiation from Vifor/Relypsa's VELTASSA (patiromer FOS)

News provided by

Spherix Global Insights

Sep 17, 2019, 13:05 ET